SCHEMBL27264382

SCHEMBL27264382

N#CCCCC(C(=O)O)c1cccc(I)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CPN1 P15169 2/20 0.42
CPB2 Q96IY4 2/20 0.42
CTSB P07858 2/20 0.40
F10 P00742 1/20 0.37
CTSS P25774 5/20 0.37
CTSK P43235 5/20 0.37
CTSL P07711 4/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TBXAS1 P24557 2/20 0.35
GRM4 Q14833 1/20 0.35
MDM2 Q00987 1/20 0.35
CYP2C19 P33261 1/20 0.33
NR3C2 P08235 1/20 0.33
FOLH1 Q04609 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27264682 0.96 CPN1 (0.41) CPN1CPB2CTSBF10CTSS
SCHEMBL31626010 0.96 CPN1 (0.41) CPN1CPB2CTSBF10CTSS
SCHEMBL31626012 0.94 CPN1 (0.40) CPN1CPB2CTSBF10CTSS
SCHEMBL31626139 0.94 CPN1 (0.40) CPN1CPB2CTSBF10CTSS
SCHEMBL27264687 0.94 CPN1 (0.40) CPN1CPB2CTSBF10CTSS
SCHEMBL27264691 0.94 CPN1 (0.40) CPN1CPB2CTSBF10CTSS
SCHEMBL31626107 0.93 CTSB (0.41) CPN1CPB2CTSBF10CTSS
SCHEMBL27264689 0.93 CTSB (0.41) CPN1CPB2CTSBF10CTSS
SCHEMBL30804980 0.85 CTSB (0.36) CPN1CPB2CTSBCTSSCTSK
SCHEMBL27263876 0.85 CTSB (0.36) CPN1CPB2CTSBCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197420-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2025-06-19 US disclosed
WO-2024054845-A1 MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2024-03-14 WO disclosed
WO-2024054845-A1 MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197420-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCB1, PKD1 CPN1 3495/4885CPB2 3031/4885CTSB 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.